Ureteroscopy With High-powered Holmium:Yag Laser Lithotripsy With & Moses

Status Recruiting

Clinical Trial Summary

The purpose of this study is to compare Moses 2.0 pulse modulation technology and the standard high powered Holmium Laser lithotripsy and how it will affect time in the operating room, time using the laser, laser energy, and stone free rates. Currently Moses 2.0 laser technology is FDA approved and currently used in practice since 2021. No study to this date has compared Moses 2.0 without pulse modulation laser technology to Moses 2.0 with pulse modulation laser technology. The study will be including kidney and ureteral stones (a kidney stone located in the tube between the kidney and the bladder) that are 6mm and greater, but less than 20 mm in size undergoing ureteroscopic treatment. High powered lasers are used for "dusting". Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.

Clinical Trial Description

On the day of surgery, the treatment assigned to the patient will be determined by chance, like flipping a coin. Neither the patient nor the study doctor will choose the treatment type. Each patient will have an equal chance of being given either surgical treatment. One group will have stones treated with high powered laser dusting with Moses 2.0 pulse modulation and the dust produced will pass spontaneously through the urine. The other group will have stones treated with standard of care high power laser fragmentation and the dust produced will pass spontaneously through the urine. The surgical procedure will not differ from the treatment a patient would receive if he/she were not in this study. 8 to 12 weeks after surgery, participants will undergo a standard of care renal bladder ultrasound (RBUS) and Kidney Ureter Bladder Abdominal X-ray (KUB) to evaluate for stones and hydronephrosis, which is swelling of the kidney due to build-up of urine. If there are abnormal findings on the RBUS or KUM at the 8 to 12 week follow-up, participants will be asked to return to the urology clinic and may have to repeat imaging to ensure participants did not develop a postoperative condition. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06346483
Study type	Interventional
Source	Northwestern University
Contact	Alyssa McDonald, MPH
Phone	312-695-8146
Email	alyssa.mcdonald@northwestern.edu
Status	Recruiting
Phase	N/A
Start date	June 9, 2023
Completion date	June 9, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04495699` - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Recruiting	`NCT04559321` - Holmium Vs Trilogy Kidney Stones GUY's 1-2	Phase 3
Completed	`NCT04332861` - Evaluation of Infection in Obstructing Urolithiasis
Withdrawn	`NCT06138327` - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria	Phase 1
Not yet recruiting	`NCT05022537` - Clinical Outcomes of Percutaneous Nephrolithotomy Following Retrograde Percutaneous Nephrostomy Access Using Novel Device in Comparison to Antegrade Access	N/A
Completed	`NCT03872843` - Opioid Free Management After Ureteroscopy	Phase 4
Recruiting	`NCT06412822` - Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone
Active, not recruiting	`NCT06437379` - Infection Control Measures for Patients Undergoing Percutaneous Nephrolithotomy	N/A
Recruiting	`NCT04997668` - Clinical Outcomes and Healthcare Economics of SOLTIVE Compared to Ho:YAG Laser in Urolithiasis	N/A
Active, not recruiting	`NCT04333745` - Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers	N/A
Recruiting	`NCT05701098` - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)	N/A
Recruiting	`NCT04389853` - Mini-PNCL vs fURS in Management of Nephrolithiasis	N/A
Recruiting	`NCT05334979` - Oxalate and Citrate	N/A
Recruiting	`NCT05591716` - Evaluation of the Efficacy and Safety of Unimodal Bilateral Flexible Ureteroscopy.	N/A
Recruiting	`NCT06209931` - RIRS With Tip Flexible Pressure-controlling Ureteral Access Sheath Versus Mini PCNLfor Kidney Stones
Withdrawn	`NCT04545528` - The Impact of Nutritional Service in the Stone Clinic on the Patient Urine Collection Results
Completed	`NCT05714423` - Outcomes in Lower Pole Kidney Stone Management Using Mini-PCNL Compared With Retrograde Intra Renal Surgery	N/A
Recruiting	`NCT03281928` - Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling	N/A
Recruiting	`NCT04835922` - Comparison of Efficacy of Intercostal Nerve Block vs Peritract Infiltration With 0.25% Bupivacaine in PCNL	N/A
Recruiting	`NCT03257306` - Magnetic Ureteral Stent Symptoms - a Comparison to Standard Ureteral Stent as Perceived By the Patient (MAGUSS)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ureteroscopy With High-powered Holmium:Yag Laser Lithotripsy With and Moses On or Moses Off

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms